<?xml version="1.0" encoding="UTF-8"?>
<ref id="bjh17168-bib-0010">
 <label>10</label>
 <mixed-citation publication-type="miscellaneous" id="bjh17168-cit-0010">
  <collab collab-type="authors">European Medicines Agency</collab> . 
  <article-title>Points to consider on implications of Coronavirus disease (COVID‐19) on methodological aspects of ongoing clinical trials. EMA/158330/2020 Rev. 1 3 (26 June 2020)</article-title>. [cited 2020 August 28]. Available from: 
  <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-implications-coronavirus-disease-covid-19-methodological-aspects-ongoing-clinical_en-0.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.ema.europa.eu/en/documents/scientific‐guideline/points‐consider‐implications‐coronavirus‐disease‐covid‐19‐methodological‐aspects‐ongoing‐clinical_en‐0.pdf</ext-link>.
 </mixed-citation>
</ref>
